Morgan [Analyst] (on behalf of Vikram Purohit)'s questions to Compass Pathways PLC (CMPS) leadership • Q3 2024
Question
Morgan, on behalf of Vikram Purohit at Morgan Stanley, asked if the delay in the COMP 005 trial would alter the patient profile or the data parameters reported at the 6-week readout. She also inquired about the impact of these delays on the development of non-TRD indications like PTSD.
Answer
Kabir Nath (Executive) stated there would be no changes to the patient profile or the planned data disclosure for the COMP 005 trial. Regarding the pipeline, he confirmed that while PTSD remains a high-interest area with compelling Phase II data, advancing that program is not funded within the current cash runway, a situation that has not changed with the recent updates.